Connect Biopharma (NASDAQ:CNTB) Stock Keeps Buy Rating at HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Thursday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

A number of other research firms also recently issued reports on CNTB. Wall Street Zen upgraded shares of Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Piper Sandler initiated coverage on shares of Connect Biopharma in a report on Friday, June 26th. They issued an “overweight” rating and a $7.00 target price for the company. Weiss Ratings upgraded shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Oppenheimer lowered their target price on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Finally, BTIG Research lowered their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.14.

Connect Biopharma Trading Down 3.5%

Shares of NASDAQ CNTB traded down $0.03 during midday trading on Thursday, reaching $0.91. 234,975 shares of the stock were exchanged, compared to its average volume of 1,436,623. The company has a market capitalization of $57.43 million, a P/E ratio of -0.77 and a beta of -0.16. Connect Biopharma has a 52-week low of $0.85 and a 52-week high of $3.82. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $1.83 and a 200-day moving average price of $2.23.

Connect Biopharma (NASDAQ:CNTB) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $0.74 million. Equities research analysts expect that Connect Biopharma will post -1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTB. Bank of America Corp DE acquired a new position in Connect Biopharma during the first quarter valued at approximately $41,000. ADAR1 Capital Management LLC acquired a new position in Connect Biopharma during the first quarter valued at approximately $1,945,000. Knott David M Jr lifted its position in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after buying an additional 187,835 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Connect Biopharma during the first quarter valued at approximately $135,000. Finally, Richmond Brothers Inc. acquired a new position in Connect Biopharma during the fourth quarter valued at approximately $489,000. 58.72% of the stock is owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.